Page 0032

arm based on the specific aberration in their tumour. One such

trial by Cancer Research UK is run in collaboration with

AstraZeneca and Pfizer, who will provide access to up to 14

different drugs - 12 from AstraZeneca and 2 from Pfizer.

We recently announced collaborations with Qiagen to

develop a diagnostic both in Europe and a companion

diagnostic in the United States. Gefitinib is the first EGFR TKI

in Europe with a label allowing the use of circulating tumour

DNA (ctDNA) obtained from a blood sample, to be used for the

SPONSORED FEATURE: ASTRAZENECA

30 CANCER CONTROL 2015

assessment of EGFR mutation status in those

patients where a tumour sample is not an option.

Roche is collaborating with us to develop a

companion diagnostic for AZD9291. Successful

drug discovery requires novel mechanisms of

collaboration across academia and industry - a more

open approach to innovation and an approach which

shares both the risks and the rewards.

In summary, the explosion of information about

the genetic aberrations underlying cancer has led to

several changes in the paradigm of how we develop

drugs for this disease. The nature of clinical trials

designed to address this new understanding is

already changing and will change further. Far from

there being a decline in innovation in pharmaceutical

development, I see that we are in one of the most exciting times

in cancer drug development with innovation in every aspect of

how we discover and develop new therapies. I have no doubt

that it is only by working together across academia and

industry and sharing our scientific expertise that we stand the

best chance of reaching our bold ambition of one day

eliminating cancer as a cause of death. l

References

1. GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in

2012. Available at: http://globocan.iarc.fr/pages/fact_sheets_population.aspx

2. Baldwin DR. Imaging in lung cancer: recent advances in PET-CT and screening. Thorax.

2011;66:275-7.

3. Davidson MR, et al. The pivotal role of pathology in the management of lung cancer. J

Thorac Dis. 2013;5(Suppl 5):S463-78.

4. Cancer Research UK. Lung cancer survival statistics. Available at:

http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/lungcancer-survival-statistics

Last accessed May 2014.

5. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic

modalities with durable clinical benefit in melanoma patients. Clin Cancer Res

2013;19:5300-9.

6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev

Cancer 2012;12:252-64.

7. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and

pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor

tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol

2002;20:4292-302.

8. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor

receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in

non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol

2002;20:3815-25.

9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of

gefitinib for previously treated patients with advanced non-small-cell lung cancer (The

IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.

10. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and

carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin

Oncol 2004;22:785-94.

11. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine

and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin

Oncol 2004;22:777-84.

12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth

factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N

Engl J Med 2004;350:2129-39.

13. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with

clinical response to gefitinib therapy. Science 2004;304:1497-500.

14. Soria JC, Mok TS, Cappuzzo F, et al. EGFR-mutated oncogene-addicted non-small cell

lung cancer: current trends and future prospects. Cancer Treat Rev 2012;38:416-30.

15. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary

adenocarcinoma. N Engl J Med 2009;361:947-57.

16. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-smallcell

lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.

17. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-smallcell

lung cancer to gefitinib. N Engl J Med 2005;352:786-92.

18. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to

gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

PLoS Med 2005;2:e73.

19. Cross D, Ashton S, Nebhan C, et al. AZD9291: an irreversible, potent and selective

third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+)

and resistance (T790M) mutations in advanced lung adenocarcinoma. [abstract]. In:

Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets

and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol

Cancer Ther 2013;12(11 Suppl):Abstract nr A109.

20. Ward RA, Anderton MJ, Ashton S, et al. Structure- and reactivity-based development

of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal

growth factor receptor (EGFR). J Med Chem 2013;56:7025-48.

21. Finlay MR, Anderton M, Ashton S, et al. Discovery of and first disclosure of the clinical

candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both

activating and T790M resistant mutations that spares the wild type form of the

receptor. [abstract]. In: Proceedings of the AACR-NCI-EORTC International

Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA.

Philadelphia (PA): AACR; Mol Cancer Ther 2013;12:Abstract nr B94.

22 Ranson M, Pao W, Kim DW, et al. AZD9291: an irreversible, potent and selective

tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M)

mutations in advanced NSCLC. World Conference on Lung Cancer Syndey Australia

October 2013.

Right target

Right tissue

Right safety

Right patients

Right commercial

potential

Research Candidate Clinical

selection

Figure 2: The 5R framework for AZD9291

Index

  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038
  39. Page 0039
  40. Page 0040
  41. Page 0041
  42. Page 0042
  43. Page 0043
  44. Page 0044
  45. Page 0045
  46. Page 0046
  47. Page 0047
  48. Page 0048
  49. Page 0049
  50. Page 0050
  51. Page 0051
  52. Page 0052
  53. Page 0053
  54. Page 0054
  55. Page 0055
  56. Page 0056
  57. Page 0057
  58. Page 0058
  59. Page 0059
  60. Page 0060
  61. Page 0061
  62. Page 0062
  63. Page 0063
  64. Page 0064
  65. Page 0065
  66. Page 0066
  67. Page 0067
  68. Page 0068
  69. Page 0069
  70. Page 0070
  71. Page 0071
  72. Page 0072
  73. Page 0073
  74. Page 0074
  75. Page 0075
  76. Page 0076
  77. Page 0077
  78. Page 0078
  79. Page 0079
  80. Page 0080
  81. Page 0081
  82. Page 0082
  83. Page 0083
  84. Page 0084
  85. Page 0085
  86. Page 0086
  87. Page 0087
  88. Page 0088
  89. Page 0089
  90. Page 0090
  91. Page 0091
  92. Page 0092
  93. Page 0093
  94. Page 0094
  95. Page 0095
  96. Page 0096
  97. Page 0097
  98. Page 0098
  99. Page 0099
  100. Page 0100
  101. Page 0101
  102. Page 0102
  103. Page 0103
  104. Page 0104
  105. Page 0105
  106. Page 0106
  107. Page 0107
  108. Page 0108
  109. Page 0109
  110. Page 0110
  111. Page 0111
  112. Page 0112
  113. Page 0113
  114. Page 0114
  115. Page 0115
  116. Page 0116
  117. Page 0117
  118. Page 0118
  119. Page 0119
  120. Page 0120
  121. Page 0121
  122. Page 0122
  123. Page 0123
  124. Page 0124
  125. Page 0125
  126. Page 0126
  127. Page 0127
  128. Page 0128
  129. Page 0129
  130. Page 0130
  131. Page 0131
  132. Page 0132
  133. Page 0133
  134. Page 0134
  135. Page 0135
  136. Page 0136
  137. Page 0137
  138. Page 0138
  139. Page 0139
  140. Page 0140
  141. Page 0141
  142. Page 0142
  143. Page 0143
  144. Page 0144
  145. Page 0145
  146. Page 0146
  147. Page 0147
  148. Page 0148
  149. Page 0149
  150. Page 0150
  151. Page 0151
  152. Page 0152
  153. Page 0153
  154. Page 0154

powered by PageTiger